City of Hope names Steven T. Rosen as Provost/Chief Scientific Officer
Current director of Northwestern School of Medicine cancer center is first in new role
DUARTE, Calif. – City of Hope has selected
Steven T. Rosen
, the director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, as its first provost and chief scientific officer. Rosen, an internationally known specialist in hematologic malignancies, will set the scientific direction of City of Hope as it embarks on a new era of strategic growth, shaping the research and educational vision for the $1.2-billion independent biomedical research, treatment and education institution.
“City of Hope has established our reputation as an academic medical institution, known for leading-edge research, superior outcomes and compassionate, patient-focused care,” said President and soon-to-be Chief Executive Officer Robert Stone
. “Dr. Rosen’s experience and vision will create the environment necessary to accelerate the pace of meaningful discoveries that extend both quality and length of life.”
At Northwestern, Rosen was widely recognized for bringing the cancer center to national prominence. There, he not only led one of the nation’s most distinguished cancer centers for more than two decades, he simultaneously provided care for hundreds of patients with blood cancers and oversaw a basic science laboratory and clinical research team credited with improving the treatment of patients with blood cancers.
He also has served as an advisor to, among other institutions, the National Cancer Institute and the American Cancer Society; has written more than 400 papers, reports, editorials and books; and has even had a day named in his honor in Chicago, Steven T. Rosen Day, for his contribution to the field of oncology.
“I feel privileged to join such a prestigious institution with so many accomplished and talented scientists, clinicians and administrative leaders,” Rosen said. “City of Hope is one of the great treasures in American medicine, with some of the most important discoveries of the last decades coming from its investigators – both in terms of scientific observations as well as clinical advances.”
“This is a unique opportunity to work with leaders as accomplished as Robert Stone, as well as the remarkable medical and nursing staff and incredibly talented scientists,” he added.
Rosen will assume his new duties on March 1, 2014. The appointment will take effect soon after Stone takes over the chief executive role from Michael A. Friedman, M.D., a former FDA acting commissioner, who is retiring Jan. 1. “This is an important time in City of Hope’s growth,” Stone said. “We’re pleased that Dr. Rosen has agreed to help shape and grow our research vision as we move forward.”